[
    [
        {
            "time": "2018-03-04",
            "original_text": "The Funded: A court fight over Johnson & Johnson's $3.4B Auris Health acquisition is going forward",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Auris Health",
                    "acquisition",
                    "court fight"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Funded: A court fight over Johnson & Johnson's $3.4B Auris Health acquisition is going forward",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "Stock Market Rallies After Fed Meeting, But Not For Long; Adobe, Rivian, Eli Lilly In Focus: Weekly Review",
            "features": {
                "keywords": [
                    "Fed Meeting",
                    "rallies",
                    "Adobe",
                    "Rivian",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare",
                    "automotive"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Stock Market Rallies After Fed Meeting, But Not For Long; Adobe, Rivian, Eli Lilly In Focus: Weekly Review",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-05",
            "original_text": "Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More",
            "features": {
                "keywords": [
                    "PFE",
                    "Arena Buyout",
                    "LLY",
                    "2021 View"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-01-10",
            "original_text": "Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022",
            "features": {
                "keywords": [
                    "Biogen",
                    "Aduhelm",
                    "Confirmatory Study"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-07",
            "original_text": "Here's Why Shares of Bristol Myers Squibb, Eli Lilly, and Pfizer Rocketed Higher This Week",
            "features": {
                "keywords": [
                    "Bristol Myers Squibb",
                    "Eli Lilly",
                    "Pfizer",
                    "rocketed higher"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's Why Shares of Bristol Myers Squibb, Eli Lilly, and Pfizer Rocketed Higher This Week",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]